Jiangxi University of Traditional Chinese Medicine
Phase
Observational
Started
2025-08-01
Last updated
2025-07-22
Condition(s) studied
Type 2 Diabetes
Study summary
This real-world study aims to investigate the association between the consumption of Pueraria lobata radix and adverse events in patients with type 2 diabetes mellitus (T2DM) under special scenarios. By retrospectively analyzing the clinical data of patients with T2DM, we will evaluate the safety profile of Pueraria lobata radix in different special populations, identify potential risk factors, and provide evidence-based support for the safe consumption and clinical use of Pueraria lobata radix.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Diagnosis with T2DM.
2. Documented history of consuming Pueraria lobata radix (PLR) in any dosage form (e.g., dried slices, root cubes).
3. Fulfillment of at least one of the following special scenarios: 1) Excessive dosage: Daily PLR intake ≥ twice the maximum dose specified in the Chinese Pharmacopoeia; 2) Long-term consumption: PLR consumption duration ≥ three months with frequency ≥ three times weekly; 3) Advanced age: ≥ 80 years; 4) Pregnancy; 5) Lactation; 6) Allergic constitution: History of any food or drug allergy; 7) Liver dysfunction: Clinical diagnosis of liver cirrhosis or chronic liver failure, or laboratory findings of total bilirubin \> 1.5 × upper limit of normal (ULN) or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \> 2 × ULN; 8) Renal insufficiency: Clinical diagnosis of diabetic nephropathy or chronic nephritis with renal function impairment, or serum creatinine \> 120% of ULN.
4. Occurrence of adverse events during the retrospective observation period within one month following PLR consumption.
Exclusion Criteria:
1. Diagnosis of type 1 diabetes mellitus, gestational diabetes mellitus, or other specific types of diabetes.
2. Use of PLR compound preparations (e.g., puerarin injection).
3. Unavailability of complete clinical data or patient refusal to provide essential information required for the observation period during follow-up.
Primary outcome measure(s)
Incidence of individual adverse events — Collect data from the past 6 months for each sample, with the sample sources spanning a two-year period The between-group differences in the incidence of individual adverse events will be compared across the eight predefined special consumption scenarios: 1) excessive dosage, 2) long-term consumption, 3) advanced age, 4) pregnancy, 5) lactation, 6) allergic constitution, 7) liver dysfunction, and 8) renal insufficiency.
Trial sites (1)
Facility
City
Region
Status
The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
Nanchang
Jiangxi
More Jiangxi University of Traditional Chinese Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.